The FDA has given the nod to two blood tests for Alzheimer’s disease. On August 20 they cleared C2N’s Precivity AD2 test. On August 24, they announced that Roche’s Elecsys p-tau217 passed muster. Both ...
Most of the known genetic risk for Alzheimer’s disease is explained by single-letter DNA changes found in genome-wide association studies. Large structural rearrangements, such as copy-number variants ...
Not all astrocyte lipid droplets are created equal. In the August 19 Nature Communications, scientists led by Priyanka Narayan at the National Institutes of Health in Bethesda, Maryland, report that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results